Mark brings 28 years of experience in the bio-pharmaceutical industry including driving the transition of multiple emerging biotechnology companies from R&D stage to commercialisation. During his career, he has focused on bringing novel therapies to market for patients with rare diseases, and has launched seven orphan drugs.
Prior to Orchard Therapeutics, Mark served as Chief Commercial Officer of PTC Therapeutics (“PTC”) where he helped transition the company from a privately funded, US-based R&D biotech to a public, commercial stage company with a 47 country commercialisation footprint. This he achieved by building a global commercialisation capability and successfully launching two rare disease therapies.
Prior to joining PTC, Mark served as Global President of Aegerion Pharmaceuticals Inc. and Head EMEA region at Shire Human Genetics. Mark received an M.A. in Natural Sciences from Cambridge University and an MBA from INSEAD.